IW Capital

IW Capital Research

Investment Thesis

IW Capital is a London-based growth equity and venture capital firm backing ambitious UK founders building technology, MedTech, and SaaS businesses. Founded around 2010-2011, the firm has grown from a tax-efficient (EIS/SEIS) retail investment platform into an active institutional-style investor with a dedicated Investment Committee. IW Capital frames its value proposition around three pillars: IW Capital (deploying capital with pace and purpose), IW Connect (long-term relationships and network access), and IW Catalyst (a dedicated in-house team supporting portfolio companies with marketing, PR, and public affairs). The firm positions itself as offering "more than capital," emphasizing speed of decision-making and hands-on, active involvement post-investment.

Sector Focus

IW Capital's portfolio skews heavily toward:

• AI-enabled MedTech and digital health (Lucida Medical's cancer-diagnosis AI, Strolll's AR neurorehabilitation, GPDQ's on-demand GP service, Flarin's OTC pharmaceutical)
• Consumer technology and AI-hardware (MAGIC AI's AI fitness mirror)
• Climate/decarbonisation and recycling (Impact Recycling's plastics recycling technology, and the realized exit SaveMoneyCutCarbon, a B2B decarbonisation platform)
• Marketing/adtech (Navigator's privacy-first, post-cookie advertising platform)
• HR tech and workplace wellbeing (Plumm Health)
• Logistics and e-commerce fulfilment (Gonini, formerly Bezos.ai)

The firm explicitly brands its focus areas on its website as "Technology/AI, MedTech, and SaaS."

Stage Focus

IW Capital invests primarily at Series A and later growth stages, generally as a lead or co-lead investor in companies that already have initial traction (NHS deployments, retail rollouts, revenue). It is not a pre-seed/seed specialist; the site markets its offering to "exceptional potential" and "ambitious founders" with existing commercial validation, and many portfolio investments are structured to qualify for the UK Government's EIS tax relief scheme.

Check Size

Based on disclosed recent rounds, typical investment size ranges from roughly £3.3M (follow-on and growth checks into Reconome, Impact Recycling, Gonini) up to £8.7M-£11M for larger Series A/growth rounds (Lucida Medical, Strolll, Omni Pet). The firm states it has deployed more than £188M across its portfolio to date (per third-party funding trackers), though this figure is not confirmed on IW Capital's own site.

Lead Tendency

IW Capital very consistently leads the rounds it participates in — press coverage across nearly every recent deal (Strolll, Lucida Medical, Omni Pet, Navigator, Gonini, Impact Recycling, Reconome) describes IW Capital as the lead investor, sometimes syndicating with smaller co-investors (e.g., Redrice Ventures on Omni Pet).

Recent Activity

IW Capital has been highly active through 2025 and into 2026:

• December 2024: £3.3M investment in Reconome (IT asset disposition/digital inclusion)
• March 2025: Led £10.35M Series A in Strolll (AR neurorehabilitation)
• June 2025: £3.3M follow-on investment in Impact Recycling
• September 2025: £4M investment in Navigator (privacy-first advertising)
• January 2026: Portfolio exit — SaveMoneyCutCarbon acquired by Haydale for £24M, an exit for IW Capital which had backed the company since 2017
• March 2026: Led £8.7M investment in Lucida Medical (AI-powered prostate cancer diagnosis), Series A
• June 2026: Led £11M growth round in Omni Pet (plant-based dog food), with Redrice Ventures
• July 2026: £3.3M investment in Gonini (e-commerce fulfilment)
• August 2026: Portfolio companies MAGIC AI (Currys retail expansion) and Lucida Medical (real-world AI evaluation results) generated fresh news coverage

Fund status reads as actively deploying, with a steady cadence of new investments and follow-ons through mid-2026.

Portfolio Highlights

Notable active portfolio companies include Lucida Medical (AI prostate cancer diagnostics, CE-marked, deployed across 15+ NHS hospitals), Strolll (AR neurorehabilitation for Parkinson's and neurological disorders, running an RCT with University of Leeds/York and four NHS trusts), MAGIC AI (AI fitness mirror sold via Currys, John Lewis, Decathlon, and Argos, and named a Fast Company Most Innovative Company for 2024), Navigator (privacy-first advertising platform used by L'Oréal, HSBC, Formula 1, FC Barcelona), Omni Pet (plant-based dog food seen on Dragons' Den), Gonini (e-commerce fulfilment across 16 countries), GPDQ (UK's first GP-on-demand app), and Flarin (OTC lipid-formulated ibuprofen). The firm's clearest realized exit is SaveMoneyCutCarbon, acquired by Haydale for £24M in a deal completed January 2026 after IW Capital had backed the company since 2017.

Team

• Tariq Attia, CEO — 15+ years at IW Capital; led a management buyout to become CEO; previously National Australia Bank Treasury and VC/PE roles.
• Alan Armstrong, Chairman — Chairs the Investment Committee; 35+ years in private equity, previously NatWest Equity Partners and Rockpool Investments; co-led the 2024 MBO.
• Andrew Brode, Investment Committee — Serial entrepreneur/investor with exits including RWS Holdings and Learning Technologies Group.
• Jasper Falk, Investment Committee — Partner at Ekins Guinness; 20+ years investment banking, formerly built JPMorgan's Global Inflation trading business.
• Toby Franklin, Investment Committee — PE fund partner focused on financial services, sits on four investee boards.
• David Fisher, Senior Investment Director — 20+ years venture/seed/scale-up investing across software, media, consumer tech and SaaS; previously Edge Investments and Elderstreet Investments.
• Alex Petri, Investment Director — 15+ years sourcing UK PE/VC and Latin American infrastructure investments.
• Isobel Egemole, Investment Director — 8+ years venture/scale-up investing across tech, consumer and healthcare; previously Midven and Future Planet Capital.
• Charlie Lyon Carroll, Investment Director — 15+ years in public markets, growth and venture capital; 8 years at Codex Capital.
• Nicholas Creek, Head of Client Services — 20+ years asset management/client servicing, previously M&G Investments.
• Michael Higley, Senior Investor Relations — 15 years small-cap PE experience in the tax-efficient investment space.
• Sara Banares, Marketing Manager — Leads brand/comms strategy; previously Future Planet Capital.

The firm operates with a formal Investment Committee structure (Alan Armstrong, Andrew Brode, Jasper Falk, Toby Franklin) that reviews and approves deals sourced by the Investment Director team.

Decision Process

IW Capital uses a formal Investment Committee process rather than solo-GP or informal partnership decision-making, per its published Investment Committee membership. The site emphasizes "precision, guided by a clear set of criteria and thorough due diligence," while portfolio founders describe the firm as "fast-moving."

Founder Preferences

IW Capital backs technology-driven founders with products that already have commercial or clinical validation — NHS deployment, retail distribution, or enterprise customers — rather than pure pre-product teams. Several portfolio companies (Lucida Medical, Strolll, GPDQ) have deep NHS/clinical relationships, suggesting a preference for founders who can navigate regulated UK markets.

Geographic Focus

IW Capital invests almost exclusively in UK-headquartered companies, consistent with its EIS/SEIS tax-relief-eligible investment structure, which requires UK-qualifying trading companies.